We investigated whether an interleukin 1 receptor antagonist (IL-1ra) altered cellular release of prostanoids and leukotrienes in a transformed colonic cell line (CACO-2) in the presence of proinflammatory stimuli. Cellular inflammation was induced by treatment with lipopolysaccharide (LPS) or the cytokine, interleukin 1 beta (IL-1β). In a separate set of experiments, cells were pretreated with IL-1ra prior to exposure to LPS or IL-1β. Prostaglandin E₂ and leukotriene B₄ (LTB₄) levels were quantified by ELISA assays. Both LPS and IL-1β exposure were noted to stimulate cellular PGE₂ release, a response which was significantly inhibited by IL-1ra treatment. Either stimulant when administered alone failed to stimulate release of LTB₄. When administered after IL-1ra pretreatment however, both stimuli caused a significant increase in LTB₄ release. These results suggest that a cytokine receptor antagonist can selectively influence eicosanoid production in this cell line. Furthermore, this study suggests that a IL-1ra may have a future clinical role in the treatment of inflammatory disorders of the colon which are intimately linked to enhanced eicosanoid synthesis.

Key words: CACO-2, Colonocytes, Cytokines, Eicosanoids, Inflammation, Leukotrienes, Prostaglandins

Introduction

Within the past two decades a large body of scientific information has surfaced regarding the molecular signals which control inflammation at both the local and systemic levels. Many inflammatory mediators have been recognized, including lipid-derived substances such as arachidonic acid metabolites, peptide regulatory molecules, and certain pro-inflammatory cytokines. A number of recent investigations of inflammatory bowel disease have focused on the role that these inflammatory mediators may play in initiating and perpetuating disease processes. Epithelial cells have been shown to produce certain cytokines under specific circumstances and recent investigation has focused on the role that various humoral mediators of inflammation including: autacoids such as platelet activating factor (PAF), eicosanoids, and cytokines play in the initiation and maintenance of intestinal inflammatory states.¹⁻³ Cytokines are known to be important in mediating many aspects of both inflammatory and immunologic responses, and it is likely that they play a similar role in initiating intestinal injury observed with inflammatory bowel disease. Similarly, LPS is known to contribute to the local inflammation and cellular toxicity associated with Gram negative infections⁴ and is itself known to lead to enhanced expression of a variety of cytokines that orchestrate inflammation, immune responses,⁵,⁶ and the release of arachidonic acid metabolites.⁷ IL-1ra is a natural monocyte protein (22KD) that has been cloned and expressed in recombinant form.⁸,⁹ It has become a useful probe to investigate the role of IL-1β in the pathogenesis of inflammatory disease states. The aim of the present study was to determine the effect of IL-1ra upon cellular release of eicosanoids in colonocytes exposed to known pro-inflammatory stimuli.

Materials and Methods

A transformed colonocyte cell line CACO-2 (American Type Culture Collection, Rockville, MD), was utilized in all experiments employing culture techniques described previously.¹⁰ Briefly, the cells were maintained in Eagle's minimum essential medium (MEM) supplemented with 20% fetal bovine serum containing gentamicin (0.1 mg/ml) and 1% non-essential...
amino acids (Sigma, St Louis, MO). The cells were grown in a 37°C, humidified, 5% CO₂ incubator, and maintained by weekly passage. The cells were plated in six-well tissue culture plates (Costar, Cambridge, MA) with an initial density of 2 × 10⁵ cells per well and allowed to grow to confluence. All experiments were conducted on cells which were 1–3 days post-confluent. The viability of the cells was assessed by trypan blue exclusion and morphology was evaluated by routine phase contrast microscopy.

Prior to the experiments, the cells were incubated for 24 h in serum free media. At the time of the experiments, the cells were washed twice with Krebs-Ringer bicarbonate buffer (KRB) and then the cells were exposed to lipopolysaccharide (10 μg/ml; Sigma Chemical, St Louis, MO) or IL-1β (0.1 μM; RND Systems, Minneapolis, MN) for 1 h. Previous studies in our own laboratory have demonstrated significant release of eicosanoids under such experimental conditions. To evaluate the effects of a cytokine antagonist on such eicosanoid release, IL-1ra (100 μg/ml; Synergen Inc., Boulder, CO) was dissolved in 5% sodium carbonate solution and diluted in KRB buffer before being added to the cells for a 1 h preincubation period prior to subsequent exposure to LPS or IL-1β. Control wells were similarly treated with 1 ml of fresh media for a similar time period. At the conclusion of the experiments, the media was collected for eicosanoid determinations and the plates frozen at −80°C until quantitative analysis of proteins was performed.

To determine protein concentrations, 0.3 ml of 1 N sodium hydroxide was added to each well and the wells were then thoroughly scraped. The resultant supernatants were collected and incubated in this solution for 1 h at 37°C. Protein levels were then determined with a BCA protein kit (Pierce Chemicals, Rockford, IL) using a microtitre plate protocol and serial dilutions of bovine serum albumin as internal standards. PGE₂ and leukotriene B₄ (LTB₄) assays were performed in duplicate in buffer solutions without separation by a competitive enzyme assay which utilizes an acetylcholinesterase tracer (Cayman, Ann Arbor, MI). The eicosanoid concentrations were determined by spectrophotometric analysis of all samples after addition of Ellman’s reagent and compared with standard curves generated under identical conditions. The data are presented as mean eicosanoid release (pg/mg protein) ± S.E.M. Statistical analysis was performed by analysis of variance with a Scheffe’s post hoc test. Significance indicates a p value < 0.05.

Results
As indicated in Table 1, unstimulated CACO-2 cells released basal levels of PGE₂ and LTB₄ into the media. Incubation of these same cells with LPS and IL-1β significantly increased the release of PGE₂, although LTB₄ levels remained equivalent to the basal state. Similarly, treatment of these cells with IL-1ra alone increased the basal release of PGE₂ but had no effect on LTB₄ levels. Interestingly, IL-1ra treatment in the presence of LPS or IL-1β reversed the noteworthy increases in PGE₂ release and led to a paradoxical increase in cellular release of LTB₄.

Discussion
The potential role that various cytokines play in the pathogenesis of inflammatory bowel disease has generated increased interest. In two models of experimental colitis, inflamed colonic mucosa were found to produce and release significantly higher amounts of IL-1 compared with normal colonic mucosa. Increased production of IL-1 as measured by bioassays and by ELISA has been reported during active disease states in both ulcerative colitis and Crohn’s disease. In support of these observations, Satsangi et al. reported that peripheral blood mononuclear cells obtained from patients with active Crohn’s disease produced significantly higher quantities of IL-1 under in vitro conditions when compared with normal control cells.

The relationship between the cytokine system and arachidonic acid pathways is complex. A variety of cellular and humoral mediators (i.e. pro-inflammatory eicosanoids) may be responsible for the mucosal damage observed in colonic inflammation. Although some cytokines are known to directly damage cells, or to augment the cytotoxicity of various leukocytes, some are known to directly stimulate the synthesis of

| Table 1. The effect of LPS (10 μg/ml), IL-1β (0.1 μM) and IL-1ra (100 μg/ml) on cellular PGE₂ and LTB₄ release |
|-------------------------------------------------|-----------------|-----------------|-----------------|
|                          | PGE₂ (pg/mg protein) | LTB₄ (pg/mg protein) |
| Untreated               | 97.4 ± 7.6        | 0.14 ± 0.03     |
| LPS                    | 510.5 ± 173.1     | 0.13 ± 0.01     |
| IL-1β                  | 612.0 ± 111.3*    | 0.11 ± 0.01     |
| IL-1ra                 | 116.5 ± 31.4**    | 0.18 ± 0.02     |
| LPS + IL-1ra           | 114.0 ± 25.1**    | 0.43 ± 0.09**   |
| IL-1β + IL-1ra         | 102.1 ± 33.9†     | 0.41 ± 0.03†    |

Note: Each value represents the mean ± S.E.M. of six values from 6 wells containing 2 × 10⁵ CACO-2 cells.
*Significant from untreated cells; **significant from LPS; †significant from IL-1β.
pro-inflammatory eicosanoids. Under these conditions, cell membrane 1-alkyl-2-arachidonoyl-1-SN-glycerol-3-phosphocholine (G3PC) is acted upon by phospholipase A₂ to form arachidonic acid and 1-alkyl-glycerol-phosphocholine (1-alkyl-GPC). Arachidonic acid in turn can be converted into eicosanoids by lipoxygenase and cyclooxygenase pathways, thus linking interleukin production with the synthesis of eicosanoids during inflammatory states.¹⁹

Our results indicate that CACO-2 cells release significant amounts of PGE₂ in response to stimulation with either LPS or IL-1β, suggesting that these stimulants have the capacity to directly regulate the synthesis of prostanoids in these cells. Since LTB₄ levels were not enhanced under these same conditions, these data further suggest that either the lipoxygenase arm of the arachidonic acid cascade does not respond in a similar manner to these same agonists, or more likely that the noted increases in PGE₂ can exhibit an inhibitory effect on LTB₄ formation in these cells. The latter concept is supported at least in part, by the work of Ham et al.,²⁰ who reported that PGE₂ directly inhibited the release of LTB₄ from activated neutrophils.

Our results also indicate that treatment of CACO-2 cells with a selective IL-1 receptor antagonist (IL-1ra) induced a significant increase in cellular release of PGE₂, suggesting a similar stimulatory effect on prostanoid synthesis in this cell line. Although an apparent explanation for these effects is lacking, such stimulation could occur if the IL-1ra had a direct biological effect on the prostaglandin cascade or if it could induce the synthesis of yet another cytokine whose effects would be mediated through endogenous prostaglandin synthesis. In support of this contention is the work of Oshima et al.,²¹ who reported that in rats injected systemically with IL-1ra, there was a significant elevation in gastric mucosal PGE₂ compared with control treated animals.

An interesting observation in the present study was the noted effect of IL-1ra pretreatment upon PGE₂ and LTB₄ levels in cells that were stimulated with either LPS or IL-1β. Under these conditions PGE₂ levels were noted to return to baseline and LTB₄ levels were noted to be significantly elevated, representing a paradoxical shift in arachidonic acid metabolism. Although not obvious, a potential explanation for the observed results could be an apparent relationship between regulatory mechanisms governing leukotriene synthesis directly by one or more prostaglandins which is intimately orchestrated by IL-1ra. Under these conditions, PGE₂ when available in sufficient amounts could exert an inhibitory effect on LTB₄ synthesis and release. If this were the case, then decreases in or inhibition of PGE₂ synthesis would obviate this inhibitory effect and result in enhanced LTB₄ as detected in this study. In support of this contention are numerous studies which demonstrate such effects in adjuvant arthritis.²²-²⁴

Thus, there is ample evidence to implicate various eicosanoids, and proinflammatory cytokines in the pathogenesis of colitis. Although most of the production of these mediators has been attributed to the inflammatory cells present in bowel wall, there is also increasing evidence for the production of some of these potentially proinflammatory compounds by the mucosal epithelial cells themselves. Thus, it is possible that epithelial cells may actually contribute significantly to the pathological process in patients with inflammatory bowel disease. Since this process has not yet been thoroughly delineated, further attempts to better characterize epithelial cell responses to initiators of mucosal inflammation, particularly with regard to the release of different types of prostanooids are warranted. A better understanding of the mechanism(s) by which the local inflammatory process in the bowel is generalized to produce these systemic signs and symptoms may further suggest new therapeutic options which could offer some palliation to these patients.

References

1. Campbell CA, Walker-Smith JA, Hindocha P, Adinolfi M. Acute phase proteins in chronic inflammatory bowel disease in childhood. J Ped Gastroenterol Nutr 1982; 1: 193–200.
2. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antitrypsin and alpha 1-glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest 1987; 17: 460–467.
3. Prantera C, Davoli M, Lorenzetti R, Pallone F, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10: 41–45.
4. Cubulsky NME, Chan MK, Movat HZ. Acute inflammation and microthrombosis induced by endotoxin, IL-1 and TNF and their implication in gram-negative infection. Lab Investigation 1988; 55: 365–378.
5. Uhlich TR, DelCastillo J, Keys M, Gruinger GA, Ni RX. Kinetics and mechanisms of recombinant human IL-1 and TNF induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987; 139: 3406–3415.
6. Dinarello CA, Cannon GJ, Wolff SM, Bemheim HA, Buttler B, Cerami A, Figari B, Pildallino MA, O'Connor IV. TNF is an endogenous pyrogen and induces production of IL-1. J Exp Med 1986; 153: 1143–1150.
7. Sirko S, Bishai I, Coccani F. Prostaglandin formation in the hypotalamus in vivo: effect of pyrogens. Am J Pathol 1989; 135: 861–8624.
8. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC. Primary structure and functional expression from complementary DNA of a human IL-1 receptor antagonist. Nature 1990; 345: 536–540.
9. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripras DJ, Heimdal PL, Armes LG, Sommers A, Eisenberg SP, Thompson RC. IL-1 receptor antagonist activity of a human IL-1 inhibitor. Nature 1990; 35: 1694–1697.
10. Stratton MD, Chandel B, Deshpande Y, Kaminski DL, Li AP, Venarno AM, Longo WE. The effect of clostridium difficile toxin on colocone prostaglandin production. Prostaglandins 1994; 48: 367.
etiology of acute acalculous cholecystitis: the effect of lipopolysaccharide of human gallbladder mucosal cells. Prostaglandins 1994; 47: 319–330.

12. Kaminski DL, Feinstein WK, Deshpande YG. The production of experimental cholecystitis by endotoxin. Prostaglandins 1994; 47: 253–257.

13. Wiechelman K, Braun R, Fitzpatrick J. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 1988; 175: 251–257.

14. Rachmilewitz D, Simon P, Schwartz DE, Griswold DE, Fondevaco JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97: 326–357.

15. Rachmilewitz D, Simon P, Sjogren R, Fondevaco JD, Wasserman MA, Dodecker E. Investigation of IL-1 activity in the intestinal mucosa of Crohn’s disease (CD) and ulcerative colitis patients. Gastroenterology 1989; 94: A363.

16. Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1: an immunological perspective. Annu Rev Immunol 1985; 2: 263–287.

17. Einer VM, Stureler RM, Elner SG, Baggiolini M, Lindley I, Kenkel SL. Neutrophil chemotactic factor (ILB) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol 1990; 136: 745–750.

18. Satsangi J, Wolsentcroft RA, Cason J, Ainsley CC, Dumonde CC, Thompson RPH. Interleukin 1 in Crohn’s disease. Clin Exp Immunol 1987; 67: 594–605.

19. Ulich TR, Busser K, Longmuir KJ. Cytokine and calcium ionophore A23187—mediated arachidonic acid metabolism in neutrophils. Cytochrome 1990; 2: 280–286.

20. Hunt EA, Soderman DD, Zanetti MJ, Dougherty HW, McCauley E, Kaebl Jr FA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci USA 1983; 80: 4549–4553.

21. Oshima A, Wakabayashi G, Shimazu M, Yoshida A, Iwata K, Kitajima M. Gastroenterology 1995; 108: A184.

22. Asprinalli RL, Cammarata PS. Effect of prostaglandin E2 on adjuvant arthritis. Nature (London) 1969; 224: 1320.

23. Zurier RB, Quagliata E. Effect of prostaglandin E1 on adjuvant arthritis. Nature (London) 1971; 1: 304–305.

24. Zurier RB, Hoffstein S, Weissmann G. Suppression of active and chronic inflammation in adrenalectomized rats by pharmacologic amounts of prostaglandins. Arthritis Rheum 1973; 16: 606–618.

Received 22 July 1996; accepted in revised form 27 September 1996.